Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 151

Similar articles for PubMed (Select 24505885)

1.

Chronic hepatitis C virus infection in 2013--quo vadis?

Prelipcean CC, Mihai C.

Rev Med Chir Soc Med Nat Iasi. 2013 Jan-Mar;117(1):7-10. No abstract available.

PMID:
24505885
2.

[Chronic hepatitis C: improved cure rates with new approved medications].

Grammatikos G, Vermehren J, Zeuzem S.

MMW Fortschr Med. 2012 Jun 21;O 154 Suppl 2:65-9; quiz 70. Review. German. No abstract available.

PMID:
22916428
3.

[Treatment of chronic hepatitis viral C: new associations].

Ouzan D.

Presse Med. 2013 Jun;42(6 Pt 1):977-82. doi: 10.1016/j.lpm.2012.06.019. Epub 2012 Sep 27. French.

PMID:
23021659
4.

A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C.

Maticic M, Luznik Z, Stepec S, Popovic P, Snedec N, Poljak M, Stanisavljevic D.

J Clin Gastroenterol. 2014 May-Jun;48(5):464-5. doi: 10.1097/MCG.0000000000000037. No abstract available.

PMID:
24275712
5.

Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?

Michielsen P, Ho E, Francque S.

Minerva Gastroenterol Dietol. 2012 Mar;58(1):65-79. Review.

PMID:
22419005
6.

Early virological response in 1220 patients with HCV (genotype lb) chronic hepatitis and cirrhosis treated with PegInterferon plus Ribavirin.

Pascu O, Voiculescu M, Gheorghe L, Micu L, Seicean A, Iliescu L, Mocan T, Ceauşu E, Mateescu B.

Rom J Intern Med. 2011;49(2):105-12.

PMID:
22303601
7.

New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.

Dusheiko G, Wedemeyer H.

Gut. 2012 Dec;61(12):1647-52. doi: 10.1136/gutjnl-2012-302910. Epub 2012 Aug 30. No abstract available.

PMID:
22936671
8.

Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation.

Knapstein J, Galle PR, Zimmermann T.

Dig Liver Dis. 2014 Jan;46(1):88-9. doi: 10.1016/j.dld.2013.08.133. Epub 2013 Sep 17. No abstract available.

PMID:
24054768
9.

Ribavirin in chronic hepatitis C: past and future.

Loustaud-Ratti V, Rousseau A, Marquet P, Denis F, Alain S.

Expert Rev Anti Infect Ther. 2009 Apr;7(3):249-53. doi: 10.1586/eri.09.5. No abstract available.

PMID:
19344238
10.

[Individualization of antiviral treatment of chronic hepatitis].

Konstantinov DIu, Konstantinova EA, Strebkova EA, Popova LL, Suzdal'tsev AA.

Eksp Klin Gastroenterol. 2013;(6):29-34. Russian. No abstract available.

PMID:
24772857
11.

Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.

Cooper C, Lester R, Thorlund K, Druyts E, El Khoury AC, Yaya S, Mills EJ.

QJM. 2013 Feb;106(2):153-63. doi: 10.1093/qjmed/hcs214. Epub 2012 Nov 17.

12.

First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder.

Al Nahdi N, Ford JA, Greanya ED, Harrigan JA, Tse I, Steinbrecher UP, Erb SR, Yoshida EM.

Ann Hepatol. 2013 Jan-Feb;12(1):156-60.

13.

Interferon stimulated genes and hepatitis C virus infection.

Asselah T.

J Interferon Cytokine Res. 2012 Dec;32(12):557-62. doi: 10.1089/jir.2012.0059. Epub 2012 Nov 14. Review.

PMID:
23151203
14.

Predictors of sustained virologic response in hepatitis C genotype 4: beyond the usual suspects.

Abdo AA, Sanai FM.

Ann Saudi Med. 2009 Jan-Feb;29(1):1-3. No abstract available.

15.

Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.

Barritt AS 4th, Fried MW.

Gastroenterology. 2012 May;142(6):1314-1323.e1. doi: 10.1053/j.gastro.2012.02.013. Review.

16.

Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation.

Reddy KR, Everson GT.

Hepatology. 2013 Sep;58(3):1181-4. doi: 10.1002/hep.26612. Epub 2013 Jul 31. No abstract available.

PMID:
23908010
17.

Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.

Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem S, Herrmann E.

Antivir Ther. 2011;16(5):695-704. doi: 10.3851/IMP1821.

PMID:
21817191
18.

Genetic factors and hepatitis C virus infection.

Thompson AJ.

Gastroenterology. 2012 May;142(6):1335-9. doi: 10.1053/j.gastro.2012.01.046. No abstract available.

PMID:
22537440
19.

Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.

Forestier N, Zeuzem S.

Liver Int. 2012 Feb;32 Suppl 1:44-50. doi: 10.1111/j.1478-3231.2011.02720.x. Review.

PMID:
22212571
20.

Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.

Ferenci P, Reddy KR.

Antivir Ther. 2011;16(8):1187-201. doi: 10.3851/IMP1934. Review.

PMID:
22155901
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk